Former Health Minister Karl Lauterbach (SPD) is criticizing the German government’s efforts regarding research into Chronic Fatigue Syndrome (Myalgic Encephalomyelitis/CFS, ME/CFS). In an interview with “Der Spiegel” Lauterbach described the currently allocated funds as “completely unacceptable” and urged for immediate improvements.
Estimates suggest the number of individuals affected by ME/CFS has nearly doubled since the onset of the COVID-19 pandemic, reaching approximately 650,000 across Germany. A disagreement is reportedly underway within the governing coalition regarding the allocation of research funding, with debates centering on whether to commit €10 or €15 million. Lauterbach argues that this is a significantly inadequate sum, suggesting that a minimum investment of €1 billion would be necessary.
Now chairing the Bundestag’s Research Committee, Lauterbach has characterized the current situation as a failure on the part of the state, citing chronic underfunding in this vital research area. He emphasized that promises made to affected individuals, including the announcement of research funding, have not translated to meaningful action.
ME/CFS is a complex condition with neurological, immunological and metabolic components, where symptoms are exacerbated by physical, mental, or emotional stress. Even minor stimuli like light, noise, or low-level exertion can trigger debilitating symptom flares for those severely affected. Many individuals with ME/CFS experience profound limitations, requiring bed rest, caregiving and often resulting in long-term disability. Currently, there are no curative medications available and treatment focuses on management strategies aimed at improving quality of life.
